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Abstract The measurement of physicochemical properties
at an early phase of drug discovery and development is
crucial to reduce attrition rates due to poor biopharmaceu-
tical properties. Among these properties, ionization, lip-
ophilicity, solubility and permeability are mandatory to
predict the pharmacokinetic behavior of NCEs (new chemical
entities). Due to the high number of NCEs, the analytical tools
used to measure these properties are automated and progres-
sively adapted to high-throughput technologies. The present
review is dedicated to experimental methods applied in the
early drug discovery process for the determination of
solubility, ionization constants, lipophilicity and permeability
of small molecules. The principles and experimental con-
ditions of the different methods are described, and important
enhancements in terms of throughput are highlighted.
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Abbreviations
ACN Acetonitrile
ADME Absorption, distribution, metabolism and
elimination
ADMET Absorption, distribution, metabolism,
elimination and toxicity
APCI Atmospheric pressure chemical ionization
API Atmospheric pressure ionization
APPI Atmospheric pressure photoionization
b Gradient steepness
BBB Blood–brain barrier
CAD Corona aerosol discharge
CAPS 3-(Cyclohexylamino)-1-propanesulfonic acid
CCD Contactless conductivity detection
CE Capillary electrophoresis
CNS Central nervous system
CNS+ Compounds crossing the blood–brain barrier
CNS− Compounds not transported into the brain
CZE Capillary zone electrophoresis
DAD Diode array detector
DME Dimethyl ether
DMSO Dimethyl sulfoxide
ELSD Evaporating light scattering detector
EOF Electroosmotic flow
ESI Electrospray ionization
FaSSIF Fasted state simulated intestinal fluid
FeSSIF Fed state simulated intestinal fluid
HEPES 4-(2-Hydroxyethyl)piperazine-1-
propanesulfonic acid
HILIC Hydrophilic interaction liquid chromatography
HPLC High-performance liquid chromatography
HTS High-throughput screening
IAM Immobilized artificial membrane
ITIES Interface between two immiscible electrolyte
solutions
k Retention factor
ki Retention factor at the initial gradient
composition
LC Liquid chromatography
Leff Effective length of the capillary
LEKC Liposome electrokinetic chromatography
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log DpH Logarithm of the distribution coefficient at a
given pH
log kIAM Logarithm of the retention factor measured on
immobilized artificial membrane columns
log kw Logarithm of the retention factor extrapolated
to 100% water
log P Logarithm of the partition coefficient
log Pa Apparent permeability coefficient
log Pe Effective permeability coefficient
log PI Logarithm of the partition coefficient of an ion
log Plip Logarithm of the partition coefficient in
liposomes/water system
log Poct Logarithm of the partition coefficient in the
1-octanol/water system
LOQ Limit of quantification
LSER Linear solvation free-energy relationship
LSS Linear solvent strength
Ltot Total length of the capillary
LYSA Lyophilized solubility assay
MEEKC Microemulsion electrokinetic chromatography
MEKC Micellar electrokinetic chromatography
MeOH Methanol
MES 2-Morpholinoethanesulfonic acid
MS Mass spectrometry
NCE New chemical entity
NMR Nuclear magnetic resonance
NQAD Nano-quantity analyte detector
ODS Octadecyl-bonded silica
PACE Pressure-assisted capillary electrophoresis
PAMPA Parallel artificial membrane permeability assay
PC Phosphatidylcholine
PC Polycarbonate
PDMAC Poly(diallyldimethylammonium chloride)
PK Pharmacokinetic
pKa Ionization constant
pKappa Apparent ionization constant
PVDF Polyvinylidene fluoride
PVS Poly(vinylsulfonate)
RI Refractive index
RPLC Reversed-phase liquid chromatography
SAR Structure–activity relationship
SDS Sodium dodecyl sulfate
t0 Column dead time
tD System dwell time
tEOF Migration time of the electroosmotic flow
marker
tG Gradient time
tm Migration time
tmc Migration time of the micelle marker
tEOF Migration time of the EOF marker
tR Retention time of a compound
U Tension
UHPLC Ultrahigh-pressure liquid chromatography
VEKC Vesicle electrokinetic chromatography
z Charge
Δϕ Change in composition of the mobile phase
during the gradient
μeff Effective mobility
Introduction
Drug research is a complex and time-consuming process. A
period of 12–20 years is needed from the discovery of new
chemical entities (NCEs) to the marketing authorization of
a new drug. This process can be divided into two main
phases (cf. Fig. 1): (i) drug discovery, which includes target
identification, hit discovery, and lead optimization; and (ii)
drug development, which comprises preclinical and clinical
studies. Inappropriate pharmacokinetic (PK) behavior has
been recognized as one of the major factors leading to the
rejection of NCEs during drug development [1]. Therefore,
a great deal of effort has been made to perform these studies
as early as possible in the drug discovery process, preferably
before the drug candidate enters the lead optimization phase.
In this way, only compounds with high potency and suitable
PK properties are selected for development [2].
Physicochemical properties (solubility, ionization and
lipophilicity) allow the ADME (absorption, distribution,
metabolism and excretion) behavior of a compound to be
predicted [3, 4]. Solubility is a parameter of prime impor-
tance in the drug discovery process. Indeed, drugs must be
soluble in order to reach their targets, and poor solubility
seems to be the most important cause of rejection during
drug discovery and development [5]. Moreover, it severely
affects results of in vitro screening bioassays.
Also, the majority of NCEs are ionizable compounds. As
the ionization state of a compound affects its solubility and
lipophilicity, and thus its pharmacokinetic behavior, early
evaluation of its ionization constants is an important step in
the discovery process [6]. Lipophilicity, which describes the
partitioning of a compound between an aqueous and a
lipidic environment, is another essential physicochemical
property impacting ADME behavior, as it widely contrib-
utes to membrane permeation, solubility, protein binding
and metabolism.
Finally, important information on advanced ADME or
PK properties such as passive drug permeability across a
phospholipidic membrane is also useful. Previously, perme-
ability experiments were generally carried out later in the
discovery process, since they were based on low-throughput
in vitro methods, often performed with biological materials.
Recently, new analytical methods based on artificial mem-
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branes or partitioning in an anisotropic medium have
emerged. These approaches are now largely implemented
in the screening processes used in pharmaceutical research as
a first predictor of biological membrane permeability.
Since advances in combinatorial chemistry have drastically
increased the number of NCEs, tools for analytical physico-
chemical and PK properties determination are automated and
progressively adapted to high-throughput technologies [6].
Indeed, although in silico prediction methods are gaining
in importance, experimental determination remains neces-
sary in order to optimize in silico methods and build
chemical libraries of experimental physicochemical data.
The present review is dedicated to experimental methods
applied early in the drug discovery process to determine
solubilities, ionization constants, lipophilicities and perme-
abilities of small molecules. The principles and experimen-
tal conditions of the different methods are described, and
the important enhancements in terms of throughput are
highlighted.
Ionization constants
Traditional methods
Potentiometric and spectrophotometric methods are com-
monly used for pKa determination.
In potentiometric titration (cf. Table 1), the pH of a
vigorously stirred solution is continuously measured with a
glass electrode as precisely known volumes of a standard-
ized strong acid or base are added [7]. The pKa is
determined from the difference between the potentiometric
titration curve of the tested compound and a blank aqueous
titration. When the solubility of a compound in aqueous
media is insufficient, co-solvents are added, and titrations at
different co-solvent concentrations allow the pKa to be
extrapolated to zero percent co-solvent [8–10]. This method
is universal and takes 30–60 min/titration (i.e., 10–30
titrations/24 h) using an automated instrument (e.g., the
Sirius GLpKa from Sirius Analytical Instruments, Forest
Row, UK). As this technique requires milligram amounts of
sample at relatively high concentrations (200–5000 μM)
[11], a microscale pH-titrimetric method was described but
is rarely used [12]. However, it remains difficult to handle
impure or unstable compounds.
Spectrophotometric pKa determination (cf. Table 1) is
based on the change in the absorption of a chromophore
near ionizable moieties [4]. This technique was recently
used for the pKa determination of lansoprazole [13] or
sartans [14]. The ionization constants are determined from a
plot of the absorbance measured at an appropriate wavelength
as a function of pH. More recently, Tam and coworkers
developed a generalized method called multiwavelength
spectrophotometric titration. It requires a diode array detector
coupled to an automated pH titrator and a much more
complex data treatment [15–19]. Spectrophotometric pKa
determination is usually more sensitive than potentiometry,
with sample concentrations ranging from 10 to 50 μM. A
microscale spectrophotometric method was also introduced
by Morgan et al. [12]. As it takes 30 min/titration, a spectral
gradient analysis (SGA) method designed for a 96-well
format and based on a pH gradient flow technique with
diode array UV detection was developed to increase the
throughput [20, 21]. A commercial SGA instrument (from
Sirius Analytical Instruments) is available, allowing the
determination of pKa values of one compound in only 4 min
(240 samples/24 h) [4]. However, this technique requires a
measurable UV chromophore that is dependent on the pH,
which is not the case for all pharmaceutical compounds [7,
DRUG DISCOVERY DRUG DEVELOPMENT
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Fig. 1 Scheme of the drug
research process
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11]. Moreover, it is also difficult to deal with impure and
unstable compounds.
Capillary electrophoresis
Theory and principles
In recent years, capillary zone electrophoresis (CZE) (cf.
Table 1) has emerged as the method of choice for pKa
determination due to some inherent advantages, as reported
in several reviews [4, 22–29]. (i) The sample and solvent
consumptions are small: 1–50 nl of sample at concen-
trations of 10–500 μM is usually introduced into the
capillary, while the whole capillary volume is about 1 μl
(for a conventional capillary of length 50 cm and internal
diameter 50 μm). (ii) Separations are performed under
high electric fields with a flat flow profile, ensuring very
thin peaks and high resolving power. (iii) The instru-
mentation is fully automated and able to handle impure
samples, as it is a separation method. (iv) This technique
is universal, since different detection systems can be coupled
to CZE [24].
With this approach, pKa determination is based on the
measurement of the effective mobility (μeff) of the analyte
at various pH values. Indeed, the μeff of a compound
depends on the molar fraction of each ionized form present
at a given pH. Practically speaking, μeff can be measured
as:
meff ¼
Leff  Ltot
U
 1
tm
 1
tEOF
 
ð1Þ
where tm and tEOF are the migration times of the analyte
and neutral marker, respectively, U is the applied voltage
(V), Ltot is the total capillary length (cm) and Leff is the
effective capillary length (cm). The variation in electroos-
motic flow (EOF) at different pH values is corrected for by
using a neutral marker, as described in Fig. 2A.
Then, pKa values are calculated by nonlinear regression
using the relationship between μeff and pH (Eq. 2). This
equation can be applied to different ionizable compounds,
depending on the number and nature of the ionizable
groups, as described elsewhere [30]:
meff ¼
Xn
i¼0
Qi
j¼1
10pKaj
" #
 10 inð ÞpH
Pn
i¼0
Qi
j¼1
10pKaj
" #
 10 inð ÞpH
 mHniXzi ð2Þ
where i and j are, respectively, the ith and jth dissociation
steps, n is the total number of ionizable groups and z in the
charge of the fully protonated species HnX
z. A typical plot
of the variation of the effective mobility of the monobasic
compound lidocaine as a function of pH is presented in
Fig. 2B.
The determination of pKa values by CZE has mainly
been applied to pharmaceutical compounds [28]. Agree-
ment with other methods is generally good (about 0.2 pKa
units), but can be much lower in the case of weak bases
(pKa<3) or weak acids (pKa>10).
Experimental conditions
To obtain reliable pKa values by CZE, several general
considerations concerning critical experimental conditions,
like the choice of the buffer (i.e., its nature and ionic
strength), the applied voltage and the detection method,
must be taken into account.
First, the buffer nature should be carefully chosen.
Rafols et al. published an extended study of this problem
[31]. Ammonium buffers should be avoided due to their
Table 1 Experimental techniques for pKa determination
Method Potentiometry Spectrophotometry CZE-UV
Measurement Ionization profile Ionization profile Single points
Quantity 2–10 mg 2–10 mg <<<1 mg
High purity Necessary Necessary Not necessary
Low/medium-throughput
instrumentation
Automatic titrator: GLpKa
(Sirius Analytical Instruments,
Forest Row, UK)
DAD-UV spectrophotometer
coupled to an automatic titrator
(various vendors)
Capillary electrophoresis unit
(various vendors)
High-throughput
instrumentation
with 96-well plate technology
- Spectral gradient analysis, SGA
(Sirius Analytical Instruments,
Forest Row, UK)
Multiplexed capillary electrophoresis:
cePRO 9600 (Advanced Analytical
Technologies, Ames, IA, USA) or
MCE 2000 (Pfizer Laboratory,
Groton, CT, USA)
Miscellaneous - Only for compounds with a
measurable chromophore that
is dependent on the pH
-
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instability, as they are highly volatile. Amino-based buffers
like butylammonium, ethanolammonium and diethanolam-
monium tend to interact with the capillary wall, generating
distortions in the curves of μeff versus pH. Some other
buffers interact with certain types of analytes, which could
affect their migration behavior [30–35]. For example, it is
well known that borate buffers interact strongly with
compounds possessing consecutive diols, like catechol.
Finally, interactions between mono/dihydrogenophosphate,
MES, HEPES and protonated amines may occur when the
pH is higher than the pKa, and similarly between borate
buffers and deprotonated amines when the pH is lower than
the buffer pKa. Therefore, taking into account the con-
straints discussed above, recommended buffers have been
extracted from the literature for the whole pH range, and
are listed in Table 2. Another important parameter
concerning buffers is their ionic strength. A constant ionic
strength should be used to avoid μeff variations and keep
activity coefficients constant. If each buffer has a different
ionic strength, corrections for ionic strength must be
calculated for each μeff measurement. Since the different
formulae used for μeff corrections are approximate [36, 37],
a decrease in the accuracy of the results must be expected
[35]. Therefore, it is easier to work at constant ionic
strength and then correct the pKa values determined with
activity coefficients for zero ionic strength. The ionic
strength is generally set to between 10 and 50 mM to
ensure sufficient buffer capacity and low Joule heating.
Buffers cover a large pH range (e.g., from 2 to 12),
generally with an increment of 1.0 pH unit. For compounds
with multiple pKa values close to one another, more buffers
should be used (for example with an increment of 0.5 pH
units) to obtain good curve fitting [38].
Temperature variations should be strictly avoided when
determining pKa values, since this parameter is dependent
on the temperature [39]. Numerous parameters influence
the temperature inside the capillary, such as the applied
voltage, the buffer conductivity, the capillary dimensions
(diameter, total length) and the thermoregulation system
(controlled by an air- or liquid-pooling system). Therefore,
the applied voltage should be adjusted to remain in the
linear region of Ohm’s law and prevent excessive Joule
heating [40]. In the absence of active cooling of the
capillary, it is possible to correct the measured mobilities
to standard temperature with empirical equations [41].
Organic or hydroorganic solvents can alternatively be
used to determine dissociation constants of water-insoluble
Table 2 Recommended buffers according to [30]
pH Buffer pKa Possible interactions
1.5–2.5 Phosphate 2.12
3.0–4.5 Formate 3.75
4.0–5.5 Acetate 4.76
5.5–7.0 MESa 6.13 Protonated amines
6.5–8.0 MOPSb 7.20 Protonated amines
6.5–8.0 Phosphate 7.20 Protonated amines
7.5–9.0 Tricinec 8.15 Protonated amines
8.5–10.0 CHESd 9.30 Protonated amines
8.5–10.0 Borate 9.24 Diols
11.5–12.0 Phosphate 12.37 Protonated amines
aMES: 2-morpholinoethanesulfonic acid
bMOPS: 3-(N-morpholino)propanesulfonic acid
c Tricine: N-tris(hydroxymethyl)methylglycine
d CHES: 2-(N-cyclohexylamino)ethanesulfonic acid
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a
Fig. 2 A Electropherograms of the monobasic compound lidocaine
and the EOF marker at different pH values: at pH 5.0 the compound is
mainly in its cationic form and migrates before the EOF, at pH 7.5 the
compound is partially ionized and migrates closer to the EOF, and at
pH 10.0 the compound is neutral and migrates with the EOF. B The
curve of the effective mobility of lidocaine as a function of pH is
sigmoidal: at pH<6 the compound is mainly present in its cationic
form and μeff is high, between pH 6 and 10 the curve shows an
inflection point corresponding to the pKa of lidocaine, and at pH>10
the compound is neutral and μeff is equal to zero
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or sparingly soluble compounds. Methanol and acetonitrile
are the organic solvents most commonly used in CZE, with
a preference for methanol as it has properties closer to those
of water. Numerous papers deal with pKa determination by
CZE in aqueous–organic solvents [33, 42–56] or nonaqueous
solvents [57–62]. Practically speaking, the pH of hydro-
organic buffers is measured with electrodes calibrated with
the usual aqueous standards, which leads to the absolute
s
wpH scale (i.e., pH measured in solvent s, relating to the
water pH scale) [63]. Then the aqueous pKa values (i.e.,
w
wpKa) can be estimated from the
s
wpKa values determined in
aqueous–organic solvents by Yasuda–Shedlovsky extrapola-
tion [64]. The pH of an organic buffer is measured with
electrodes calibrated with organic standards prepared by
mixing equimolar quantities of acids and their conjugates
with known sspKa values. This leads to the relative
s
spH scale
(i.e., pH measured in solvent s, relating to the solvent pH
scale). The wwpKa values can be estimated from nonaqueous
solvents by means of linear extrapolation equations derived
for similar types of compounds [41].
The UV detector is the preferred one for pKa determina-
tion by CZE, as it is sensitive enough for the majority of
pharmaceutical compounds. Moreover, it enables a simulta-
neous spectrophotometric determination of pKa values (i.e.,
from UV spectra measured at the maxima of the electro-
phoresis peaks), as described by several authors [51, 65–
68]. The pKa values of non-UV-absorbing compounds can
be determined by indirect UV detection [69, 70], ampero-
metric detection [71] or contactless conductivity detection
(CCD) [30, 36, 37]. The latter is particularly interesting, as
it can be easily implemented in CZE and may provide
interesting complementary information to photometric detec-
tion. Finally, mass spectrometry (MS) can be coupled to CZE
[72]. This detector presents several advantages in terms of
sensitivity and universality. Furthermore, several compounds
can be analyzed simultaneously due to its high selectivity,
increasing the throughput of pKa determination. However,
the big challenge of pKa determination by CZE-MS is to find
volatile and stable enough buffers for the whole pH range.
Towards high-throughput methods
Numerous efforts have been recently made to increase the
throughput of pKa determination by CE. A major challenge
with conventional CE methods is the long migration times
at low pH due to the limited EOF. An interesting way to
overcome this problem is to use dynamic coatings. For
anions, a suitable strategy consists of using a positively
charged coating, generally polybren, in negative mode [69,
73–75]. Neutral polyacrylamide coatings eliminating the
EOF can be utilized for cations in positive mode and anions
in negative mode [32, 43, 76]. Finally, the most generic
strategy is to employ a double coating (polybren and poly
(vinylsulfonate) (PVS) or CEofix®), thus creating a high
EOF whatever the buffer pH [14, 30, 77].
The use of short capillaries is not recommended due to the
high electric fields, which generate significant Joule heating.
On the other hand, short-end injection is a good strategy as it
reduces the effective length of the capillary without
enhancing Joule heating [14, 30, 55, 72, 78, 79]. The latter
strategy coupled with a dynamic coating procedure enabled
pKa determination in about 2 h per compound [30].
To increase the throughput, pressure-assisted capillary
electrophoresis (PACE) was developed for pKa determina-
tion [67, 79–84]. The application of an external pressure of
up to 2 psi does not seem to affect pKa determination but it
does increase peak broadening. Therefore, it may decrease
the precision of tm and tEOF determination, and μeff
measurement. The throughput of such a PACE method
was reported to be about 20 compounds per day [81, 82],
but it can be further increased to 50 compounds in less than
3 h using MS detection due to sample pooling [72].
The throughput obtained by instruments with a single
capillary is limited by the number of experimental points
needed to fit the curves of μeff versus pH. More recently,
several applications using vacuum-assisted multiplexed
96-channel capillary electrophoresis with UV detection
have been reported for high-throughput pKa screening (24
compounds/h) [23, 56, 85–87]. The ability to adapt existing
single-capillary electrophoresis methods to a multiplexed
instrument proves that CE has its place in drug discovery
and development.
Lipophilicity
Lipophilicity is expressed as the logarithm of the partition
coefficient (log P) for partitioning between two immiscible
solvent phases, and is valid for a single electrical species
[88]. The distribution coefficient, expressed as log DpH,
refers to the weighted contributions of all electrical forms
of an ionizable compound present at a given pH [22]. The
1-octanol/water system is the widely accepted reference
system for the determination of lipophilicity.
Traditional methods
The classical shake-flask technique has little evolved over the
decades but remains the reference method for lipophilicity
measurement [89]. Briefly, the compound is mixed with two
immiscible solvents, generally water and 1-octanol, until
equilibrium is reached. Then the two phases are separated
and the solute concentration is usually measured in both of
them. However, this procedure is tedious, time-consuming
and sensitive to impurities. It is also prone to emulsion
problems and requires large amounts of sample. Therefore,
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in the last decade, different strategies have been developed
to speed up, automate and miniaturize the shake-flask
approach. An automated shake-flask system for high-through-
put log D measurement (48 samples/day, in duplicate) was
described by Hitzel et al. [90]. The entire liquid handling is
performed by a robotic system, and the partitioning process
takes place on a 96-well plate. After shaking, each phase is
directly injected from the plate into the LC-UV system with
an auto-injector. A fast generic gradient allows the concen-
tration of the solute of interest to be measured. An alternative
is to use an LC-MS system [91]. A commercially available
instrument using an automated and miniaturized shake-flask
method is manufactured by Analiza (Cleveland, OH, USA)
[92, 93]. More recently, a high-speed log D (HSLogD)
measurement system based on automated sampling was
developed to reduce contaminations from the 1-octanol phase
when sampling the water phase [94]. This contamination was
prevented by aspirating a plug of water before sampling the
water phase. Despite all of these improvements, this
technique still requires some time-consuming steps that
multiply the manipulations involved, like the mutual satura-
tion and decantation of both phases. In addition, the
measurable log Poct range remains limited (from −3 to 4).
When dealing with ionizable compounds, dual phase-
potentiometric titration is possible. This method is based on
the pKa shift that occurs in the presence of a partitioning
solvent, for instance 1-octanol. A large difference between the
true and apparent pKa values indicates a large log P value. A
log P determination requires two titrations and directly
provides a distribution profile rather than single points [22].
This method presents the same features as pKa determination
in terms of sample consumption and concentration, and the
same automated instrument (Sirius GLpKa from Sirius
Analytical Instruments) can be used. However, this tech-
nique is only appropriate to ionizable compounds, and it is
difficult to handle weak lipophilic bases with low pKa or
weak acids with high pKa values.
Cyclic voltammetry at the interface between two immis-
cible electrolyte solutions (ITIES) is the method of choice for
studying the log P of ions (log PI) [22, 95]. The distribution
of a particular ion at the ITIES is determined by how similar
its electrochemical potentials in the two phases are, and log
PI can be deduced from the Nernst equation at the ITIES.
Capillary electrophoresis
Theory and principles
As reported in several reviews [23, 25, 26, 29, 96–102],
capillary electrophoresis is emerging as an interesting
separative method for log Poct determination due to its
inherent advantages, as enumerated in the relevant subsec-
tion of “Ionization constants” (also, cf. Table 3). For this Ta
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purpose, a CE mode that is able to separate neutral analytes
(i.e., one combining the features of conventional CE and
LC) is needed. Therefore, different CE modes (including a
pseudo-stationary phase) have been tested, namely MEKC,
MEEKC and VEKC/LEKC (micellar, microemulsion and
vesicle/liposome electrokinetic chromatography, respectively).
MEKC is an electrokinetic chromatography technique
that uses buffers containing micelles as a pseudo-stationary
phase. The separation of neutral compounds is due to
differential partitioning between aqueous and micellar phases.
Micellar pseudo-stationary phases, commonly sodium
dodecyl sulfate (SDS), are considered to mimic biological
membranes better than 1-octanol or RPLC stationary phases
[25]. Practically speaking, log Poct determination by MEKC
is based on the measurement of the retention factor k:
k ¼ tR  tEOF
1 tRtMC
 
 tEOF
ð3Þ
where tR, tEOF and tMC are the migration times of the analyte,
neutral marker and micelle marker, respectively. Highly
hydrophilic neutral compounds such as acetone are used as
EOF markers, whereas highly lipophilic compounds such as
dodecaphenone are selected as micelle markers. Good linear
correlations were found between log k (measured by MEKC)
and log Poct for a wide variety of compounds and conditions
[103–122]. However, congeneric behavior was observed
[108, 116] and confirmed by LSER analyses, which demon-
strated differences in H-bond basicity and dipolarity/polariz-
ability for partitioning into SDS micelles or the 1-octanol/
water system [98].
LEKC and VEKC are also electrokinetic chromatography
techniques that use liposomes or vesicles (i.e., bilayer
structures enclosing an aqueous core region) as a pseudo-
stationary phase [102]. Linear correlations between log k
measured by LEKC/VEKC (Eq. 3) and log Poct were
reported [123–126], and these techniques appear to mimic
physiological membranes more closely than ME(E)KC
[127]. However, vesicles and liposomes are unstable and
difficult to prepare reproducibly. Therefore, their use
remains limited for log Poct determination [99].
Another electrokinetic chromatography technique using
buffers containing nanometer-sized oil droplets (MEEKC)
has been widely used, as it is the most appropriate CE mode
for log Poct determination. MEEKC separations are based
on the same principles as MEKC, LEKC and VEKC.
Numerous linear correlations between log k measured by
MEEKC (Eq. 3) and log Poct were reported in the literature
[86, 128–145], and calibration curves with standard com-
pounds generally allowed accurate log Poct determinations
over a large log Poct range (from −1 to 7) [133–136, 140,
142, 144]. Indeed, microemulsion systems are known to be
more stable and reliable than MEKC for log Poct estimation
[129], as they more closely resemble phospholipidic
vesicles than SDSmicellar systems do [128]. LSERs analyses
also suggest that microemulsion systems are good models
for the 1-octanol/water partitioning process [142, 146].
However, it should be noted that the investigated acidic or
basic compounds must be in their neutral forms, since their
ionized forms may generate ion pairs with surfactants and
additional electrophoretic migration. This additional electro-
phoretic migration can be corrected for when ion-pair
interactions are not involved or are very weak [147].
Experimental conditions
The most critical experimental conditions for log Poct
measurement by MEEKC, like the composition of the
microemulsion system, need to be pointed out.
Microemulsions are complex ternary mixtures of water,
oil and surfactant. Therefore, the microemulsion buffers
used in MEEKC are made up of many different compo-
nents. Variations in the nature and concentrations of these
components can affect the microemulsion stability and
migration. Microemulsions are stabilized by a surfactant
and a cosurfactant, which both reduce the interfacial tension
between the oil–water interface. The cosurfactant molecules
lie between the surfactant ones at the surface of the
microemulsion, thus reducing the repulsion between the
surfactant head groups. The most widely used surfactant,
oil and cosurfactant in MEEKC are SDS (anionic), heptane
and 1-butanol, respectively [99, 148–151]. A typical micro-
emulsion system used for log Poct determination consists of
6.5% w/w 1-butanol, 0.8% w/w heptane and 1.4% w/
w SDS. However, some authors have used concentrations
of up to 3.3% w/w SDS, both to increase the micro-
emulsion stability and to widen the separation window,
especially for compounds with high log Poct values [142].
Although phosphate and phosphate/borate buffered
systems have mainly been used for log Poct measurements,
zwitterionic buffers such as CAPS are being used more and
more due to their lower conductivities [142]. Indeed, even
if temperature has less of an effect on log Poct than pKa
measurements, accurate and reproducible results should be
obtained in a thermostated environment [89].
Most applications were performed with UV detection. To
the best of our knowledge, MS detection has not been used
to increase the throughput of log Poct determination by
MEEKC. Indeed, microemulsion buffers contain nonvola-
tile components such as SDS, which could generate ion
suppression as well as ionization source contamination and
clogging. Therefore, the sensitivity decreases dramatically
when using ESI-MS detection [26]. To overcome this
problem, it is now possible to switch from ESI (electro-
spray ionization) to APPI (atmospheric pressure photoion-
ization) in CE. Indeed, the latter offers a higher
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compatibility with nonvolatile buffers and has a similar
sensitivity to CE-ESI-MS [152–154].
Towards high-throughput methods
As for pKa determination by CZE, several efforts have
recently been made to increase the throughput of log Poct
determination by MEEKC.
A major problem is the long migration time at low pH due
to the limited EOF. Microemulsion systems usually contain
an anionic surfactant (SDS) and are used under alkaline con-
ditions. However, it is sometimes necessary to work at low
pHwhere the EOF is limited or even nonexistent, for example
when determining log Poct values of acidic compounds. To
overcome this problem, the polarities of the electrodes can
be reversed. However, separate experiments with positive
polarity are needed to determine the EOF mobility. A more
elegant solution to this problem is to use sulfonic acid-coated
[132, 133] or dynamically coated capillaries with adsorbed
bilayer structures such as poly(diallyldimethylammonium
chloride) (PDMAC) and PVS [138] or polybren and PVS
[139], which provides a sufficient EOF at low pH.
Other rapid approaches for log Poct determination have
been developed. For instance, pressure-assisted MEEKC
can improve the throughput to up to 48 samples per day
using a single-capillary system [135], while an instrument
and software dedicated to this experiment in an automated
format with 96 parallel capillary channels allow high-
throughput log Poct determinations (46 compounds/h) [86,
140, 142]. The latter is probably the most interesting
strategy for drug discovery and development.
Liquid chromatography
Theory and principles
The general methodology of lipophilicity determination by
LC has been the subject of several reviews [89, 96–98,
100–102, 155–159]. Indeed, the indirect reversed-phase
liquid chromatography (RPLC) approach is considered to
be the best alternative to the direct shake-flask method for
lipophilicity assessment, since it offers numerous advan-
tages (cf. Table 3). (i) The sample consumption is small:
100 μl of sample at a concentration of 10–500 μM. (ii) The
instrumentation is fully automated, compatible with the 96-
well plate format, and the sample throughput is high. (iii)
There is no requirement for highly pure samples, as it is a
separation method. (iv) This technique is universal, since
different detection systems can be coupled to LC. (v) The
measurable log Poct range is large (from −1 to 8).
The ability of RPLC techniques to assess lipophilicity
relies on the similarity between the retention mechanism on
RPLC stationary phases and octanol–water partitioning.
The determination of log Poct by RPLC is based on the
measurement of the retention factor k of the investigated
compound between the mobile and stationary phase:
log k ¼ log tR
t0
 1
 
ð4Þ
where tR is the retention time of the investigated compound
and t0 is the column dead time. The extrapolation of log k
values to 100% water, which leads to log kw values, is a
convenient means of standardizing chromatographic lip-
ophilicity parameters.
Lipophilicity measurements can be performed in either
isocratic or gradient mode. Under isocratic conditions, log k
values are calculated from tR measurements at various
concentrations of the organic solvent in the mobile phase
(Eq. 4), as described in Fig. 3A. When using methanol,
isocratic log k values are linearly correlated with the organic
modifier percentage ϕ in the mobile phase (as exhibited
by Fig. 3B):
log k ¼ log kw  S  ϕ ð5Þ
where S is a constant that depends on the nature of the
compound and the organic modifier. With acetonitrile, the
correlation between log k and the organic modifier
percentage in the mobile phase is quadratic [160]:
log k ¼ log kw þ B  ϕþ A  ϕ2 ð6Þ
where A and B are constant for a given compound and
organic modifier.
Numerous linear correlations between log Poct and log
kw obtained in isocratic mode have been reported in the
literature for different classes of compounds [161, 162], as
also shown in Fig. 3C. Valko et al. also observed linear
relationships between log Poct and ϕ0, which correspond to
the organic modifier concentration (from 0 to 100%) that
produces an equimolar distribution between the stationary
and mobile phases (i.e., when log k=0) [163, 164]. Finally,
it should be noted that several linear correlations between
log Poct and isocratic log k values at different organic
modifier percentages have been described [165–173].
However, all these linear relationships are generally better
with structurally related compounds (cf., congeneric behav-
ior) or a low number of analytes.
Gradient approaches were proposed to speed up lip-
ophilicity determination. They are generally based on the
linear solvent strength (LSS) theory elaborated by Snyder
and Dolan, where the analyte retention time (tR) in a linear-
gradient separation can be expressed as follows [174]:
tR ¼ t0b  log 2:3  ki  bþ 1ð Þ þ t0 þ tD ð7Þ
where ki is the k value at the initial isocratic composition of
the gradient, t0 is the column dead time (min), and tD is the
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system dwell time for gradient elution (min). The gradient
steepness parameter b can be described by the following
relationship:
b ¼ t0 Δϕ  S
tG
ð8Þ
where tG is the gradient time from the beginning to the end
of the gradient (min), and Δϕ is the change in composition
during the gradient (from 0 to 1). The two unknown
parameters ki and S in Eqs. 7 and 8 can be obtained from
two gradient runs differing only in gradient time. These two
values then allow estimation log kw directly with Eq. 5
when using methanol or Eq. 6 when using acetonitrile.
Appropriate calculation procedures for log kw and S are
included in available modeling software, such as Drylab
(Rheodyne, Rohnert Park, CA, USA) or Osiris (Datalys,
Grenoble, France) [175–177]. An alternative strategy which
does not require complex calculation procedure involves
assuming that S is constant for structurally similar com-
pounds. Although this approach is evidently less accurate
than the former, it allows estimation log kw from a single
gradient run [92, 178–182]. Based on this assumption,
Valko and coworkers introduced the chromatographic
hydrophobicity index (CHI), derived from the ϕ0 scale
[183–188]. Numerous linear relationships between a reten-
tion parameter obtained in gradient mode and log Poct or
log D values have been reported in the literature. In
conclusion, it can be stated that the gradient mode is a
more generic and faster strategy than the isocratic mode.
However, data treatment remains complex and it is not as
accurate as the isocratic mode [175, 189, 190].
Experimental conditions
The choice of several experimental conditions, such as the
organic modifier and the stationary phase, is crucial for log
Poct determination by RPLC.
Mobile phase Methanol and acetonitrile are the two organic
modifiers most commonly employed for log Poct determi-
nation. In the literature, methanol was generally preferred to
acetonitrile [89, 101, 160]. Indeed, quadratic extrapolation
(Eq. 6) is less accurate than linear extrapolation (Eq. 5)
[191]. Moreover, as a protic solvent, methanol can interact
with free silanol groups, reducing secondary interactions
between analytes and silanol groups. Additionally, during
equilibration, MeOH molecules form a monolayer at the
surface of the stationary phase, which provides a hydrogen-
bonding capacity in better agreement with 1-octanol/water
partition [157].
In the last few years, many authors have shown that the
addition of a small amount of 1-octanol to the methanol
fraction of the mobile phase (usually 0.25% V/V) and the
use of 1-octanol-saturated buffers improves the correlation
between log Poct or log D and log kw values, especially in
the case of basic compounds [157, 192–201]. Octanol
seems to form a coating on the silica support of the column
during equilibration, conferring octanol-like properties to
the stationary phase. Additionally, it may act as a weak
masking agent, reducing secondary interactions caused by
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100% water by linear regression. C Calibration line allowing the
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residual silanol groups [201]. However, the precise mech-
anism through which 1-octanol influences the retention is
still not fully established. It should also be noted that the
addition of 1-octanol to the mobile phase is a tedious and
time-consuming strategy due to the saturation of buffers
and the long equilibration times, which are crucial for the
repeatability of the measurements.
Stationary phases Octadecyl-bonded silica (ODS) station-
ary phases have been used extensively for lipophilicity
measurements for over 30 years. However, silanophilic
interactions due to the free silanol groups (including
hydrogen bonding as well as electrostatic interactions)
interfere in the partitioning mechanism of these columns.
To overcome this problem, apolar and polar end-capped
stationary phases were developed. However, the latter had no
real advantage over classical ODS columns for log Poct
determination [202]. On the contrary, polar embedded
stationary phases with an amide, carbamate, ether or
sulfonamide group are considered better than endcapped
ones for lipophilicity estimation due to the electrostatic
shielding provided by the polar group, thus reducing the
access to the free silanol groups [202]. However, other
interactions between polar embedded groups and analytes
may occur. More recently, high pH-resistant stationary phases
allowing log Poct determination of highly basic compounds
have been launched, such as bidentate stationary phases and
organic/inorganic hybrid stationary phases [201]. Hybrid
stationary phases with embedded polar groups are the best
choice for lipophilicity determination by RPLC [202]. Using
such columns, there is no need to add a masking agent such
as triethylamine and n-decylamine because of the lower
amount of free silanols. Finally, monolithic silica stationary
phases were also tested for fast lipophilicity determination,
but their use remains limited [182].
Immobilized artificial membrane (IAM) columns [156,
158, 203] were widely investigated for lipophilicity deter-
mination. Briefly, IAM columns contain different types of
phospholipidic monolayers covalently bonded to silica
particles and are generally less retentive than ODS columns
due to their polar head groups. They allow direct measure-
ment of log kw values for compounds with moderate
lipophilicity, while up to 30% acetonitrile is used in the
case of highly lipophilic compounds. There is not always a
clear relationship between retention properties measured by
IAM chromatography (log kIAMw or log kIAM) and log Poct
values. For neutral and acidic compounds, log kIAMw values
are generally linearly correlated with log Poct values despite
a less hydrophobic environment. However, there is a
systematic deviation in the case of basic and zwitterionic
compounds. Indeed, the retention mechanism on IAM
columns is based not only on lipophilic interactions but
also on specific ionic interactions, which are particularly
important with positively charged compounds that interact
with the phosphate anions of the stationary phase [200].
Consequently, retention on IAM stationary phases is only
moderately affected by the presence of positive charges.
The distribution coefficients measured in a 1-octanol/water
system may thus underestimate the potential of positively
charged compounds to interact with biomembranes [204–
207]. Practically speaking, IAM chromatography raises
several issues, since its retention properties are dependent
on the experimental conditions and a column-aging
phenomenon was reported by several authors [156, 208].
Recently, a new approach using hydrophilic interaction
chromatography (HILIC) has been applied to lipophilicity
determination. This separation mode is based on polar
stationary phases (underivatized silica or silica bonded with
polar groups like diols, amide, cyanopropyl, aminopropyl)
with partly aqueous eluents containing a relatively hydro-
phobic miscible solvent, generally acetonitrile [209–212].
The retention mechanism is considered to be a complex
mix of partitioning and adsorption of the compounds
between the eluent and a water-rich layer partially immobi-
lized at the surface of the polar stationary phase. There are a
number of different interactions depending on the mobile
and stationary phases involved: hydrophilic retention when
high proportions of organic modifiers are used in the mobile
phase, and a reversed-phase-type retention when the mobile
phase contains high proportions of water. An additional ion
exchange mechanism may occur on ionic HILIC stationary
phases [213, 214]. Bard et al. measured retention factors of
highly basic compounds in their cationic forms on a ZIC-
pHILIC stationary phase based on a grafted polymeric layer
with sulfoalkylbetaine zwitterioinic moieties on a wide-pore
silica. As lipophilicity expresses the difference between
hydrophobicity and polarity, the difference between the
isocratic log k values measured at 0% and 95% acetonitrile
(Δlog k0-95) was linearly correlated to their log Poct values
(r2=0.93) [213]. Therefore, this method offers a new and
promising way to measure log Poct values of highly basic
compounds without working under extreme pH conditions.
From a practical point of view, it should be noted that it is
necessary to strictly control the nature of the buffer, the pH
and the ionic strength, as the retention mechanism implies
ion exchange (ionic competition).
Detection methods UV detection is commonly used for log
Poct determination by LC. However, some alternative
detectors have also been used to deal with UV-inactive
compounds. For instance, refractive index (RI) and evap-
orating light scattering detectors (ELSD) were used in
several studies because of their quasi-universality [165,
171, 213]. In the last few years, several other aerosol-based
detectors have been launched. Corona aerosol discharge
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(CAD) and nano-quantity analyte detectors (NQAD), which
are also able to deal with nonchromophoric compounds, are
potentially more interesting than RI and ELSD due to their
higher sensitivity. Finally, if the cost per analysis is not an
issue, the detector of choice is MS, due to its high
selectivity and quasi-universality. Indeed, the different
atmospheric pressure ionization (API) sources available
(electrospray ionization, atmospheric pressure chemical
ionization and atmospheric pressure photoionization, ESI,
APCI and APPI, respectively) allow a wide variety of
compounds to be dealt with [168, 181, 185, 190, 215–218].
Towards high-throughput strategies
Several strategies were applied to speed up lipophilicity
determination by LC, such as the use of short columns and
high flow-rates. Both approaches decrease the analysis time and
extend the range of measurable log Poct. However, they cause a
significant reduction in the chromatographic performance
and the accuracy of the results [179, 180, 184, 193, 195].
Recently, the development of columns packed with small
porous particles (sub-2μm) has enabled a substantial
improvement of chromatographic performance in LC.
Indeed, this technology enables a significant time reduction
without compromising efficiency. However, such columns
generate high backpressures (<1000 bar) and require
dedicated instrumentation [219–221]. An ultrahigh-pressure
liquid chromatography (UHPLC) system was used for log
Poct measurements, offering a significant increase in the
throughput (by at least a factor of 12 compared to HPLC)
[190, 222]. Moreover, due to the stability of Acquity BEH
Shield RP18 hybrid columns at high pH (up to 11), log Poct
values of basic compounds with pKa values ranging from
6.3 to 10.3 could be determined. However, these basic
compounds displayed a different behavior from the optimal
set of calibration compounds selected by cluster analysis.
Nevertheless, accurate log Poct values of basic compounds
could be obtained in isocratic mode with 1-octanol addition or
when using isocratic log k values at 50% methanol [190, 222].
The latter strategy is very interesting in terms of average log
Poct determination time, since a single run is required (ca.
5 min per compound). Finally, MS coupling allowed the
throughput to be further increased (by an additional factor
of 10) due to sample pooling. It should be noted that precise
knowledge of the column dead time, extra-column volume
and delay time is mandatory and extremely critical in UHPLC
configuration for accurate retention factor determination.
Simultaneous determination of pKa and log Poct
Kaliszan et al. developed methods allowing the simulta-
neous determination of pKa and log Poct values from a set
of experiments carried out on the same HPLC instrument.
Apparent pKa and log Poct values could be determined in 3–
4 gradient runs. Two organic modifier gradient runs
allowed log Poct values to be determined (see the “Theory
and principles” subsection of the “Liquid chromatography”
section) and the organic modifier percentage to be
estimated, providing an appropriate retention coefficient
for the nonionized analyte. Then, one pH-gradient run
carried out with the previously determined eluent compo-
sition and one isocratic run to get the retention factor of the
ionized form allowed the apparent pKa values to be
determined [175, 176, 189, 223–225]. The obtained log
kw values correlated well with log Poct values. However,
there was only a poor agreement with literature pKa values.
Therefore, this generic approach was further improved and
a second method requiring 9 or 18 pH/organic modifier
double-gradient runs was evaluated. Its success was limited,
as the correlation with log Poct values was lower than that
seen for the previous method, and there was only a
moderate agreement with literature pKa values [226, 227].
Moreover, this strategy is time-consuming (9–18 runs) and
requires complex data treatment.
Solubility
Solubility measurements are fundamental in drug absorp-
tion, as insufficient solubility can interfere with both
pharmacokinetic and pharmacodynamic properties.
Two solubility values can be measured depending on the
experimental method used, namely thermodynamic or
kinetic solubility. Solubility assays in discovery and
development must be adapted to phase properties and
requirements (Table 4). In drug development, high-quality
solubility data are needed by chemists to facilitate appro-
priate decisions to be made so as to overcome potential
solubility liabilities. Additionally, solid-state properties
(purity, degree of crystallinity, particle size and polymor-
phism) of the tested compounds are studied and character-
ized in detail. Therefore, an evaluation of thermodynamic
solubility is required and is often considered the gold
standard. Nevertheless, it is becoming increasingly com-
mon to measure it earlier in the discovery process.
Solubility measurements are also performed in biorelevant
media to identify in vitro/in vivo correlations in accordance
with the Biopharmaceutical Classification System (BCS)
[228, 229]. This classification has been developed to
identify the fundamental rate-limiting biopharmaceutical
factors of intestinal drug absorption, and classifies drug
compounds into four classes based on their solubility and
intestinal permeability (Fig. 4). This system typically takes
aqueous solubilities measured in buffer media across the
whole pH range 1–7.5 as input.
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In drug discovery, kinetic solubility is the most relevant
parameter for rapidly evaluating whether the compound,
which is generally predissolved in dimethyl sulfoxide
(DMSO), stays in solution after dilution in specific
screening media. Incomplete solubility could indeed lead
to unreliable results, underestimated activity, reduced HTS
hit rates and an inaccurate structure–activity relationship
(SAR) when not identified [230]. For these reasons,
experimental conditions are adapted to the conditions of
the bioassay.
Reference methods
Thermodynamic solubility
The shake-flask method is considered the method of
reference for solubility measurement. An excess of solid
sample is added to the medium in a flask, and the resulting
suspension is shaken until equilibrium solubility (i.e.,
thermodynamic solubility) is reached, generally after 24 h.
Undissolved sample is then removed by filtration or
centrifugation, and the concentration of the compound in
the filtrate is determined. Effects of crystal lattice and
polymorphic forms are considered in this process, which is
important, as they can significantly influence the solubility
[231]. Therefore, thermodynamic solubility is often consid-
ered the “true” solubility of a compound. Nevertheless, this
method suffers from several weaknesses: (i) relatively large
amounts of compounds (several mg) are required to
perform the measurements; (ii) the individual weighing
step is time-consuming and difficult to automate [232]; and
(iii) long incubation times are required to reach equilibrium
solubility. Therefore, this method is mainly used in
advanced studies of lead compounds, which are often
Table 4 Differences between the methods used for solubility measurement in drug discovery and drug development processes
Discovery Development
Compounds tested
Number 100–1000 10
Quantity available A few mg > g
Purity Limited Improved
Solid state Amorphous or partially crystalline (not
characterized)
Stable, crystalline material (characterized)
Distribution Generally in DMSO stock solutions Generally in solid form
Methods
Type of solubility measured Kinetic solubility (fully dependent on experimental
conditions)
Thermodynamic solubility
Throughput High Low 25–50 compounds a week
Automation Fully Only partially automated
Format 96-well or 384-well microplates Small scale (single tube)
Incubation time Minutes Hours or days
Detection UV, turbidity HPLC-UV, HPLC-MS
Media Aqueous >20 (aqueous, organic, biorelevant media,
formulations, excipients…)
Data generated and intended
purpose
Solubility in screening bioassay media to avoid
misinterpretation
Solubility and dissolution in biorelevant media
Rank-order hits Evaluation of formulations
Characterization and optimization of solid state
Selection of promising compounds
Development of adequate strategies to overcome
solubility problems
Solubility
Pe
rm
ea
bi
lit
y
Class I
High permeability
High solubility
Class II
High permeability
Low solubility
Class III
Low permeability
High solubility
Low permeability
Low solubility
Class IV
Fig. 4 Schematic representation of the Biopharmaceutical Classifica-
tion System
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different from the crystal form used during early discovery
stages [231].
Kinetic solubility
In contrast to thermodynamic solubility, kinetic solubility
measurements are based on the precipitation of a predis-
solved compound (in a cosolvent or, for ionizable com-
pounds, in aqueous media by pH adjustment) after dilution in
a given medium. Kinetic solubility measurement is not a
substitute for thermodynamic solubility evaluation, because
crystal lattice disruption is neglected in this process.
Moreover, the solubility is not measured at equilibrium, and
the appearance of a precipitate is strongly time-dependent.
The potentiometric titration approach first introduced by
Avdeef [233–235] is the reference method for kinetic
solubility measurements. With this method, solubility
measurements are based on the difference between the
aqueous drug pKa measured in the absence of a solid phase
and the apparent pKa pKappa
 
determined in the presence of
an excess of solid compounds. The shift observed is
proportional to the loss of compound, and thus to the
solubility. Two commercial systems, pSol and CheqSol, are
currently available. As the potentiometric method allows
reliable measurements of kinetic solubility without cosolvent,
this technique is often used to calibrate high-throughput
solubility methods and computational procedures [2]. This
approach requires only small amounts of compounds [236]
and provides a complete solubility pH profile with a limited
number of experiments. Therefore, it allows a better
understanding of solubility behavior throughout the gastro-
intestinal tract [235]. However, this technique, suitable for
ionizable compounds, needs an accurate knowledge of the
pKa of the molecule to obtain reliable solubility values, and
is too slow for screening applications.
A simplified version of this methodology, named “chasing
equilibrium,” has recently been proposed [237] and validated
[238]. This technique, which is based on the same principle
as the traditional potentiometric titration method, is faster
since the intrinsic solubility of the compound (i.e., the
solubility of the neutral form) is determined instead of its
entire pH/solubility profile. With this method, it is possible
to measure the intrinsic solubility of a drug within 20–
80 min (medium throughput). The approximate pH/solubility
profile can then be calculated using Henderson–Hasselbach
relationships.
Towards high-throughput methods
Considering the large number of compounds and the small
amount of sample available at this stage of discovery,
small-scale (generally 96-well format), compound-sparing
and fully automated methods are necessary. Several HTS
methods, in which compounds are introduced as dimethyl
sulfoxide (DMSO) stock solutions into aqueous media, have
been described. These HTS methods that perform kinetic
measurements were designed to evaluate if the compounds
dissolved in DMSO remain soluble after dilution in the
aqueous screening media. Indeed, incomplete solubility
could lead to unreliable results [230]. For this purpose,
experimental conditions are adapted as much as possible to
bioassay conditions, and final DMSO percentages ranging
from 0.33% [239] to 5% [240, 241] have been reported in
the literature.
Two different approaches are commonly used. In the first
one, the formation of a precipitate, which is an indicator of
the solubility limit, is detected (turbidimetric methods). In
the second strategy, the precipitates are removed and the
concentration of the solubilized fraction of the compound is
determined.
In the turbidimetric method first introduced by Lipinski
[231], small aliquots of DMSO stock solutions are added to
buffer media each minute. The formation of precipitate is
determined by measuring light scattering using a nephelo-
metric turbidity detector in the 620–820 nm range. Further
adaptations of this methodology were then proposed to
keep the DMSO concentration in the buffer constant during
addition and to scale down the method to a 96-well plate
format [240–243]. The main drawbacks of these approaches
are (i) the relatively low sensitivity of the detection, which
does not allow compounds with very low aqueous solubil-
ities (<20 μM) to be ranked [244], and (ii) their sensitivity to
impurities.
In the second approach, small aliquots of DMSO stock
solutions are diluted with aqueous buffer in a filter
microplate to obtain a final DMSO percentage varying from
1 to 5% (v/v). When compounds present a poor aqueous
solubility, precipitation occurs and precipitates are removed
by filtration or centrifugation. Solubilities are then deter-
mined by measuring the concentrations of the solubilized
fractions of the compounds using UV detection [241, 244,
245], HPLC [241, 244] or more recently UHPLC-MS
[246]. This technique has been shown to be more sensitive
and less subject to erroneous results caused by impurities
than the turbidimetric method [244]. Undissolved material
can also be removed by centrifugation instead of filtration.
According to Alsenz et al. [5], both methods give comparable
results. Nevertheless, divergent results can be observed for
hydrophobic compounds due either to nonspecific adsorption
on filter material or to the sample floating on the surface of
the solvent in the case of centrifugation. However, filtration
through filter microplates is faster than centrifugation [5].
Even if these HTS methods are very useful for evaluating
solubility in screening bioassay media, solubility values are
generally overestimated in comparison with thermodynamic
solubility [247]. This phenomenon is attributed to the
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cosolvent effect [244, 247] and the formation of supersat-
urated solutions [247, 248]. Moreover, solubility data
obtained from different kinetic methods involving different
experimental conditions are not intended to be comparable
[237], as the appearance of a precipitate from a supersat-
urated solution is a slow process. Therefore, kinetic
solubilities should not be taken as input data for ADMET
prediction tools [5], and HTS methods allowing solubility
measurements in good agreement with thermodynamic
solubility thus remain highly desired [228, 249].
These limitations have encouraged researchers to find
solutions for measuring thermodynamic solubility during
the drug discovery process in order to obtain high-quality
solubility data [5, 250]. One solution was to evaporate the
solvent before starting the assay, thus allowing the
thermodynamic solubility to be measured. This procedure
was named the lyophilized solubility assay (LYSA) by
some authors [5], and various protocols using DMSO
[251], ACN [252], or MeOH/DME [253] as solvents for
stock solutions have been described. This method gave
solubility values in acceptable agreement with the thermo-
dynamic solubilities [5].
Adapting standard protocols of kinetic solubility meas-
urements is another approach used to minimize the effect of
predissolution in DMSO. A recent study [247] showed that
the increase in solubility registered using kinetic solubility
methods was mainly due to the formation of supersaturated
solutions with slow precipitation kinetics [247]. Supersat-
uration is a metastable state that is minimized by increasing
the shaking rate and enhancing the incubation time to 24 h.
These simple adaptations of experimental conditions were
sufficient to give results in good agreement with shake-
flask solubility without DMSO [247].
As the discrepancy between thermodynamic and kinetic
solubility values may also be due to the difference from the
solid state, Sugano et al. [254] proposed a modified version
of kinetic solubility methods where the solid form of the
precipitant was analyzed by polarized light microscopy
analysis. It was reported that the solubility of the crystalline
form could be lowered by up to 100-fold compared to that
of the amorphous state [255], or 2–5-fold among crystal
polymorphs [256]. Therefore, this technique provides a
breakthrough in the measurement of high-quality data in
early drug discovery.
Pharmaceutical companies are also looking for a HTS
version of the shake-flask method. Miniaturized shake-flask
methods requiring a minimal amount of sample (<1 mg) for
the determination of equilibrium solubility have recently
been proposed [236, 257]. However, the throughput of
these methods remains relatively low (up to 30 compounds
a week), essentially because the accurate distribution of
solid compounds into vials or wells of a microplate is still a
time-consuming and difficult to automate process. Even if
new developments appear in the field of automated powder
weighing systems [258], only a limited weighing accuracy
(±15% for 2 mg, ±10% for more than 10 mg) can be
obtained at the moment for a set of compounds with diverse
properties [5].
Biorelevant solubility
The determination of biorelevant solubility is also neces-
sary to evaluate whether the solubility could be a factor that
limits absorption (e.g., in the gastrointestinal tract). It has
been shown that drug solubility is enhanced in the intestine
in comparison with aqueous buffers due to the presence of
bile salts and lecithin. These amphiphilic components can
self-assemble to form micelles, increasing the solubility of
lipophilic compounds [259, 260]. They also act as wetting
agents, enhancing the dissolution rate of drugs [261].
Moreover, after food intake, the levels of bile salts increase
considerably, which could enhance the absorption of poorly
soluble drugs. Therefore, two different in vitro intestino-
mimetic media with biorelevant pH values [262] and bile
salt concentrations [263] have been developed to evaluate
dissolution and solubility in the small intestine: FeSSIF and
FaSSIF, which simulate the fed and fasted state conditions,
respectively. In these media, sodium taurocholate was
chosen as a model bile salt, while lecithin was added to
better mimic in vivo conditions, as it is always cosecreted
with bile salts in a 4:1 ratio [260]. The compositions of
these media have recently been updated to better represent
the compositions and the characteristics of gastrointestinal
fluids [264]. As in vitro biorelevant media are quite
expensive, these solubility studies are generally performed
in the advanced stages of drug development.
A HTS UV method was successfully adapted to measure
biorelevant solubility in two different in vitro intestino-
mimetic media (FaSSIF and FeSSIF), and excellent
correlations were obtained with FaSSIF and FeSSIF
solubility data measured by the shake-flask method
(without DMSO) [247]. Thus, this method provides a
reliable high-throughput method for measuring intestino-
mimetic solubility during the early stages of drug discovery.
Moreover, this method requires low amounts of sample,
and the expensive components of these intestino-mimetic
media (taurocholic acid and lecithin) are added as small
volumes of a separated solution, thus decreasing the cost of
these experiments.
Permeability
Permeation properties of drugs are an important challenge
in pharmaceutical research. A large number of models
(from in silico to in vivo) exist to mimic the main biological
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barriers (in particular intestinal, percutaneous and blood–
brain barriers). The different models have some inherent
advantages and drawbacks, and each of them can be useful
at a given step of the discovery and development process of
drug candidates.
In this review, emphasis is placed on the most important
methods developed to evaluate membrane permeation at the
early stages of drug discovery. These methods are based on
lipophilicity measurements in the liposomes/water system
(providing better information on membrane permeation
than the lipophilicity in the octanol/water system) and on
artificial membranes.
Partitioning into liposomes as a predictor of passive
transport
Lipophilicity measured in isotropic systems such as
octanol/water systems accounts only for the partitioning of
the neutral form, since ionic interactions are not expressed.
Therefore, these systems are not the most appropriate model
for in vivo drug distribution. In contrast, an organized
phospholipid bilayer accounts for both hydrophobic and ionic
interactions, like a biological phospholipidic membrane. For
this reason, partitioning in a liposomes/water system is
believed to be a better model for biological membrane
permeability assessment. Lipophilicity measurements of
neutral compounds are known to be comparable in octanol/
water and liposomes/water systems, but ionic compounds
partition better in a liposomes/water system than in an octanol/
water system [265].
The determination of log P in a liposomes/water system
(log Plip) can be achieved via two types of methods: direct
methods (potentiometry, equilibrium dialysis and NMR) or
indirect methods (capillary electrophoresis, HPLC). Since
direct approaches have been recently reviewed [266, 267],
only highlights are exposed here.
As with isotropic systems (such as the octanol/water
system), the determination of partition coefficients of
ionizable molecules in a liposomes/water system by potenti-
ometry is based on the shift observed between the ionization
constant measured in aqueous solution (pKa) and the
ionization constant obtained in the biphasic liposome/water
system pKappa
 
. Indeed, log P is directly related to the
difference between pKa and pKappa . This method has the
great advantage of being continuous. Therefore, it is
possible to obtain a complete lipophilicity profile (log D
vs pH). Experimentally, several solvents or anisotropic media
can be used for potentiometric titrations. However, this
method remains relatively time- and compound-consuming
in comparison with new approaches based on 96-well
technology for the evaluation of membrane permeability.
Furthermore, in addition to the usual limitations arising from
the determination of log P in isotropic systems, the use of
liposomes presents some additional issues in terms of pH
range, which should not exceed 3.5–10.5 pH units due to
the ionization of phospholipids at lower pH values and
hydrolysis at higher pH values [266].
To overcome the fastidious separation of the liposomes
and aqueous phases in the traditional shake-flask method, a
dialysis technique was proposed to avoid centrifugation
and/or filtration steps. In the dialysis experiments, a
chamber containing a liposomal suspension in a buffer
solution is separated from a second chamber containing the
analyte in a buffer solution by a semipermeable membrane.
When the equilibrium between the two phases is reached,
the solute concentrations in the two compartments can be
determined, and a distribution coefficient is then calculated
[266, 268, 269]. Radiolabeled solutes (if available) can be
used [268–271] to limit the amount of compound needed
and thus to be able to work with solute concentrations
below the saturation level for the liposomes. This method is
commonly reported for the determination of liposome/water
partition coefficients, but suffers from several drawbacks.
The determination of a complete lipophilicity profile is
tedious and expensive as it is a single-point technique.
Furthermore, generic methods are required in the early
stages of drug discovery. With the dialysis technique, many
parameters must be optimized for each tested compound.
Therefore, the use of this method for high-throughput
screening is impossible. Nevertheless, a dialysis technique
coupled to HPLC and LC-MS has recently been applied to
bring out the permeant components of a natural product
extract [272]. The dialysis technique allows compounds of
interest to be “filtered” and ranked in terms of potential
permeation through biological membranes, while chro-
matographic separation and UV (DAD) and/or MS data
allow the identification of each “filtered” compound. It is
evident that optimal experimental conditions cannot be
applied for each component of the extract, and it still takes
a long time to reach equilibrium. However, the number of
compounds screened simultaneously and the acceptable
differentiation of their affinities to liposome membranes make
this approach useful.
NMR spectroscopy has also been used to evaluate
liposomes/water partition coefficients. The affinity of
solutes for liposomes is evaluated using the relaxation rate
of hydrogen and carbon nuclei. When the solute interacts
with phospholipids, its relaxation time changes. A series of
half-height line width measurements for different phospho-
lipid concentrations are performed to evaluate the degree of
interaction between solute and liposomes (since the signal
broadening is a linear function of phospholipid concentra-
tion) [273]. One of the main advantages of this method is
that it provides informative data on the interactions between
liposomes and solutes. However, it cannot be considered a
direct technique for obtaining true log P liposomes/water
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values. Furthermore, even if this technique is faster than
equilibrium dialysis, it remains slower than potentiometric
titration [266].
The direct methods described above can be considered
medium-throughput methods. Liquid chromatography is
largely used to enhance the throughput of physicochemical
profiling, particularly for lipophilicity determination [25,
100, 102]. In terms of permeability predictions, liposome
electrokinetic chromatography (LEKC) provides an inter-
esting way to obtain log Plip values or direct correlations
with in vivo permeability data. LEKC is a capillary
electrophoresis mode with buffers that contain liposomes.
In this case, the liposomes act as a pseudo-stationary phase.
Lipophilicity in the liposomes/water system was obtained
using different types and concentrations of phospholipids
for a series of β-blockers [124], and recently permeabilities
across the skin barrier [274], the blood–brain barrier [275]
as well as intestinal absorption [276] have been targeted.
Finally, LEKC possesses some of the advantages of
chromatographic techniques but also the limitations associ-
ated with the use of liposomes [277] (see above for theory,
principles and experimental conditions).
Towards high-throughput methods
An alternative way to evaluate partitioning in liposomes
based on the use of TRANSIL® was also proposed [278,
279]. TRANSIL® is a solid (silica beads)-supported lipid
bilayer consisting of different lipids or lipid mixtures. The
analyte is added along with the TRANSIL® material to a
vial or a well containing buffer. After two minutes of
incubation, the beads are separated by filtration or low-speed
centrifugation, and the supernatant is collected for quantifi-
cation. The concentration of the analyte remaining in solution
is then compared to a control vial or well containing
compounds without TRANSIL® [279–281]. This technique
was recently adapted for HTS application, using 96 or 384
wells, and is now available as “ready-to-go” plates
(Sovicell, Leipzig, Germany), where the only pipeting
operation required is to add the analytes [282]. Detection
can be achieved using a UV reader plate, HPLC or LC/MS,
depending on the compounds. UV detection remains the
most rapid technique and is appropriate for almost 60–70%
of the tested compounds. Even though the method is based
on biological materials, the reproducibility of the assay on
three “ready-to-go” plates shows good results.
Artificial membranes as HTS methods
PAMPA technique
PAMPA (parallel artificial membrane permeability assay) is
a recent technique developed for the early evaluation of
passive transport permeability. In PAMPA, a donor and an
acceptor compartment are separated by a 96-well filter plate
supporting a liquid artificial membrane, which mimics a
biological barrier. The 96-well donor plate receives a buffer
solution containing the analytes, and the acceptor plate
initially contains a fresh buffer solution. The two compart-
ments are assembled into a "sandwich-like" configuration
and incubated for a determined time. After the incubation
time, the sandwich is disassembled and the concentrations
of compounds in both donor and acceptor compartments
are determined and compared to the initial concentration in
the donor compartment (the reference concentration).
In PAMPA, the effective (log Pe) or apparent (log Pa)
permeability coefficients are determined by single-time-
point sampling, thus allowing high-throughput measure-
ments. The equations used to calculate the permeability
coefficients can be deduced in several ways according to
the experimental conditions and to the design of the in vitro
assay, as well described by Avdeef et al. [7]. Therefore,
different equations must be used to obtain permeability
coefficients in different cases. For example, when the
retention of compounds in the membrane cannot be neglected,
sink conditions are applied using different pH buffers in the
acceptor and donor compartments (single sink conditions),
and a protein serum is added to the acceptor compartment
(double sink conditions) (for the equations, see [7]).
Depending on the nature of the artificial membrane,
different biological barriers can be targeted. The first model
published in 1998 by Kansy and coworkers consisted of an
egg lecithin membrane immobilized on a PVDF (poly-
vinylidene fluoride) filter [283]. The results showed a
hyperbolic relation between the quantity of compounds that
reached the acceptor compartment after the incubation time
and human absorption data. However, the steep slope
obtained complicates the evaluation of absorption for
compounds presenting lower passive transport. Various
membrane compositions were proposed, and the use of a
mixture of phospholipids also improved the permeability
predictions [284]. Later, Faller and coworkers proposed an
adaptation of this technique for the prediction of intestinal
absorption with hexadecane immobilized on polycarbonate
(PC) filters [285]. The main advantage of this membrane is
that it avoids the variability inherent to biological materials.
A good correlation between effective permeability coef-
ficients and percentage of intestinal absorption in humans
was obtained for a series of structurally diverse compounds.
Since then, the PAMPA technique has been applied to blood–
brain barrier (BBB) penetration studies using porcine brain
lipids in dodecane [286]. In this case, it has been shown that
dodecane plays a crucial role, whereas lipids only slightly
influence permeability, except for medium permeants, for
which the dodecane/lipids ratio must be controlled [287].
However, the latter artificial membrane allows a ranking of
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compounds according to the in vivo classification CNS+
(compounds crossing the BBB) and CNS− (compounds not
transported into the brain).
An adaptation of the PAMPA technique has recently
been proposed in order to mimic a percutaneous barrier
[288]. This artificial membrane is composed of a mixture of
isopropyl myristate (30%) and silicone (70%), and allows
human skin permeability to be predicted, as well as the
affinities of tested compounds for the stratum corneum, in a
simple and rapid way.
Liquid chromatography coupled to MS detection has
proven its capacity to increase the sensitivity of PAMPA
experiments, particularly for poorly soluble compounds or
compounds with no or low UV chromophores. Results have
shown that MS detection provides greater sensitivity and
better selectivity. Therefore, it can advantageously replace
the more commonly used UV detection method. However,
MS detection considerably decreases the throughput of the
assay and should be used only for problematic compounds
[289]. More recently, the use of UHPLC coupled to MS
detection has been proposed [287, 290]. This method
enables the concentrations of the compound to be deter-
mined in the reference, donor and acceptor compartments in
triplicate in ∼40 min at pH 2 (i.e., fourfold faster than with
LC/MS(/MS) procedures) [291]. Furthermore, the through-
put of the PAMPA assay with UHPLC/MS(/MS) was
enhanced by injecting more than one compound at a time
(sample pooling). However, this approach failed when the
compounds were similar (in terms of retention factors, m/z
ratio and/or fragmentation pathways) or when the com-
pounds exhibit very low permeation [290]. Cassette
incubation was also performed in brain penetration studies
using PAMPA [287]. Standards were tested in four sets of
six compounds, and permeability results were not signifi-
cantly different from the permeability coefficients obtained
for compounds incubated separately. Finally, the time
required to determine the permeability coefficients dropped
to 4.5 min for six compounds when both multiple-
incubation and UHPLC/MS detection strategies were com-
bined. As with the multiple-injection approach, the similarity
of compounds remains potentially problematic, but this
multiple-incubation method avoids the dilution step. There-
fore, LOQ remains equal to the one expected in single-
incubation experiments. Even though the throughput of
permeability studies can be greatly enhanced with multiple-
injection/incubation, interactions between compounds can
occur during separation and/or incubation and should be
controlled.
Immobilized artificial membrane chromatography (IAMc)
Immobilized artificial membrane chromatography has been
developed to better mimic biomembranes. IAMs are based
on phosphatidylcholine (PC) linked to a silica propylamine
surface. Three typical phases have been widely used: IAM.
PC.DD (a single acyl chain PC lipid phase), IAM.PC.DD2
and IAM.PC.MG (double acyl chain PC lipid phases with
an ester linkage). IAM.PC.DD2 and IAM.PC.MG differ in
terms of the end-capping of the residual amine [96].
However, only two of them are still commercialized
(IAM.PC.DD2 and IAM.PC.MG), since IAM.PC.DD suf-
fers from premature aging [292, 293]. The use of these
stationary phases for lipophilicity determination has been
widely reviewed [156, 158], in particular their ability to
predict passive transport through diverse biological mem-
branes [156]. In summary, the retention mechanism involved
in the IAM stationary phase differs from the one involved in
C18 columns or in the partitioning in an octanol/water
system [294], particularly for basic compounds, which are
more strongly retained on IAM columns due to polar effects
of the linked phospholipids. Furthermore, ionic interactions
between the anionic phosphate groups of the stationary
phase and positively charged compounds have been demon-
strated [200], as also reported for partitioning in phospho-
lipids [295]. Therefore, IAM columns were tested for
liposome/water partitioning, but it was noted that the
correlation between the chromatographic index obtained
and log Plip depends on the nature of the solute and the
phospholipids [296].
Studies on series of compounds showed that IAM
retention factors obtained when using IAM.PC.DD, IAM.
PC.DD2 and IAM.PC.MG were potential predictors of
human intestinal absorption and brain penetration [156,
297]. All of these studies revealed that even though kIAM
describes permeation better than other physicochemical
parameters, such as log Poct, it is still not sufficient and
must be corrected for the molecular weight or using a
combination of calculated molecular descriptors and a
solubility parameter.
Conclusion
In this review, experimental methods for the determination
of solubility, ionization constants, lipophilicity and perme-
ability applied early in drug discovery process were
discussed, and important enhancements in terms of
throughput were highlighted.
Although potentiometric and spectrophotmetric methods
are still employed for pKa determination, capillary electro-
phoresis is a valuable alternative in drug discovery and
development, especially when multiplexed instruments are
used.
The RPLC approach presents some obvious advantages
for lipophilicity determination, particularly when using
columns packed with small particles under ultrahigh-pressure
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conditions (UHPLC). Indeed, it offers a significant increase
in the throughput compared to the shake-flask method, which
remains tedious. Nevertheless, the potential of MEEKC for
log Poct measurements should be further investigated to take
better advantage of the similarity of microemulsion systems
to phospholipidic membranes.
HTS methods leading to kinetic solubility values are
convenient in the early discovery process, as compounds
are usually predissolved in DMSO. The HTS UV method is
a good compromise for solubility measurements due to its
versatility. Additionally, different solubility information can
be obtained by adapting the experimental conditions. The
solubility under particular conditions or in particular media
can thus be obtained prior to screening bioassays. More-
over, controlled experimental conditions can lead to
solubility values that are very close to thermodynamic
“true” solubility, which can be used as input for ADME
prediction tools.
The TRANSIL® and PAMPA approaches can be consid-
ered the most potent methods for rapid passive transport
studies. In the TRANSIL® method, the lipophilicity in a
liposomes/water system can be measured with good accura-
cy and reproducibility due to the commercialization of
“ready-to-go” plates, even though the method is based on
biological material. In the PAMPA method, the nature of the
artificial membrane allows the variability associated with
biological materials to be avoided. Furthermore, the cou-
pling of UHPLC with MS/(MS) detection permits the
injection of more than one compound (sample pooling),
which drastically increases the throughput and also opens up
a new avenue for the analysis of more complex mixtures.
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